EGFR and medullary thyroid gland carcinoma: Vandetanib, a small-molecule tyrosine inhibitor targeting vascular endothelial growth factor receptor (VEGF) and epidermal growth factor receptor (EGFR) as well as RET kinase, is commonly used to treat locally advanced or metastatic inoperable medullary thyroid carcinoma [83,84,85].